Tiong A H, Richardson J S
Department of Pharmacology, University of Saskatchewan, Saskatoon, Canada.
J Recept Res. 1989;9(6):495-508. doi: 10.3109/10799898909066073.
(-)-[125I]-Iodocyanopindolol [-)ICYP), used to characterize beta adrenoceptors on membrane preparations from rat cerebral cortex, was shown to have affinity for both beta adrenoceptors and serotonin receptors. Therefore, 10 microM serotonin was added to the assays to prevent (-)ICYP binding to serotonin receptors. Under these conditions, (-)ICYP binding to the cortical membrane preparation was reversible and saturable, and the association reaction was very slow. The dissociation reaction was also very slow, and revealed two affinity states corresponding to a high and a low affinity state. Scatchard analysis showed a single class of binding sites with an equilibrium dissociation constant (KD) of 20.7 pM, and a maximal density of binding sites (Bmax) of 95.1 fmol/mg membrane protein. Displacement binding analyses revealed a potency series of (-) isoproterenol greater than (-) epinephrine equal to (-) norepinephrine, suggesting a predominance of the beta 1 adrenoceptor subtype. Detailed competition ligand binding studies with the selective beta 1 adrenoceptor antagonist ICI-89406 and the selective beta 2 adrenoceptor antagonist ICI-118551, showed that about 70% of the beta adrenoceptor population in the rat cortex is of the beta 1 subtype with the remainder being of the beta 2 subtype. We conclude that since (-)ICYP binds to both beta adrenoceptors and serotonin receptors, it is important to prevent the binding of (-)ICYP to serotonin receptors by adding a suppressing ligand like excess cold serotonin when assaying beta adrenoceptors. We have presented the first such characterization of rat cerebral cortical beta adrenoceptors with (-)ICYP in this study.
用于表征大鼠大脑皮质膜制剂上β肾上腺素能受体的(-)-[¹²⁵I]-碘氰吲哚洛尔[(-)ICYP],被证明对β肾上腺素能受体和5-羟色胺受体均具有亲和力。因此,在测定中加入10微摩尔的5-羟色胺以防止(-)ICYP与5-羟色胺受体结合。在这些条件下,(-)ICYP与皮质膜制剂的结合是可逆且可饱和的,并且结合反应非常缓慢。解离反应也非常缓慢,并显示出对应于高亲和力状态和低亲和力状态的两种亲和力状态。Scatchard分析显示存在一类结合位点,其平衡解离常数(KD)为20.7皮摩尔,结合位点的最大密度(Bmax)为95.1飞摩尔/毫克膜蛋白。置换结合分析显示(-)异丙肾上腺素的效价顺序大于(-)肾上腺素等于(-)去甲肾上腺素,表明β₁肾上腺素能受体亚型占优势。用选择性β₁肾上腺素能受体拮抗剂ICI-89406和选择性β₂肾上腺素能受体拮抗剂ICI-118551进行的详细竞争配体结合研究表明,大鼠皮质中约70%的β肾上腺素能受体群体为β₁亚型,其余为β₂亚型。我们得出结论,由于(-)ICYP与β肾上腺素能受体和5-羟色胺受体均结合,因此在测定β肾上腺素能受体时,通过添加过量冷5-羟色胺等抑制性配体来防止(-)ICYP与5-羟色胺受体结合非常重要。在本研究中,我们首次用(-)ICYP对大鼠大脑皮质β肾上腺素能受体进行了此类表征。